» Articles » PMID: 2378567

A Recombinant Vaccinia Virus Expressing Hepatitis B Virus Middle Surface Protein. Restricted Expression of HBV Antigens in Human Diploid Cells

Overview
Journal Arch Virol
Specialty Microbiology
Date 1990 Jan 1
PMID 2378567
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Several vaccinia virus recombinants inducing the synthesis of the middle surface (M) protein of hepatitis B virus (HBV) were constructed. One of them, denoted v137, was examined in some detail. The virus replicated nearly to the same extent in various cell lines, viz. human embryo diploid fibroblast LEP and MRC-5 cells, rabbit embryo fibroblast REF cells, TK- rat RAT-2 cells, and green monkey CV-1 cells. However, the production of M protein was found considerably lower in the human LEP and MRC-5 than in the other cells examined. In addition, the kinetics of M formation were different in these two cell systems, LEP cells lagging significantly behind CV-1 cells. The low-level production of M protein in LEP cells was not increased by repeated v137 passages in LEP cells, nor by a passage in a laboratory worker accidentally infected with the v137 virus, nor by shortening the leader sequence preceding the translation initiation codon. The greater part of the M antigen was found to be cell associated, more so in the cells of human than monkey origin. From the major HBV S antigen (HBsAg) isolated from the plasma of chronically infected subjects, the antigen released by cell destruction differed by binding to polymerized human albumin. This property was utilized in ELISA to detect anti-preS2 antibody. Rabbits inoculated intradermally with the v137 virus developed antibodies reactive in this assay as well as with a synthetic peptide corresponding in the amino acids 14-34 of the NH2 terminus of the HBsAg preS2 region.

Citing Articles

Comparison of Immune Response in Mice Immunized with Recombinant PreS2/S-C18-27 Protein Derived from Hepatitis B Virus with Commercial Vaccine.

Parizad E, Fooladi A, Sedighian H, Behzadi E, Valizadeh A, Khosravi A Iran J Pathol. 2022; 17(4):448-460.

PMID: 36532644 PMC: 9745760. DOI: 10.30699/IJP.2022.553785.2896.


Comparative purification and characterization of hepatitis B virus-like particles produced by recombinant vaccinia viruses in human hepatoma cells and human primary hepatocytes.

Reuschel E, Jilg W, Seelbach-Goebel B, Deml L PLoS One. 2019; 14(2):e0212800.

PMID: 30794666 PMC: 6386438. DOI: 10.1371/journal.pone.0212800.


Hepatitis B virus proteins expressed by recombinant vaccinia viruses: influence of preS2 sequence on expression surface and nucleocapsid proteins in human diploid cells.

Kutinova L, Nemeckova S, Hamsikova E, Zavadova H, Ludvikova V, Broucek J Arch Virol. 1994; 134(1-2):1-15.

PMID: 8279947 DOI: 10.1007/BF01379102.


Priming effect of recombinant vaccinia virus coding for the middle hepatitis B surface antigen.

Hamsikova E, Zavadova H, Kutinova L, Ludvikova V, Krchnak V, Nemeckova S Arch Virol. 1990; 113(3-4):283-9.

PMID: 2222186 DOI: 10.1007/BF01316681.


Synthesis and immunogenicity of hepatitis B virus envelope antigen expressed by recombinant vaccinia virus. Finding of retention signal in the C-terminal portion of the preS1 domain of subtype adyw.

Nemeckova S, Kutinova L, Hamsikova E, Kunke D, Press M, Zavadova H Arch Virol. 1991; 121(1-4):29-41.

PMID: 1759909 DOI: 10.1007/BF01316742.

References
1.
Cheng K, Moss B . Selective synthesis and secretion of particles composed of the hepatitis B virus middle surface protein directed by a recombinant vaccinia virus: induction of antibodies to pre-S and S epitopes. J Virol. 1987; 61(4):1286-90. PMC: 254096. DOI: 10.1128/JVI.61.4.1286-1290.1987. View

2.
Chelyapov N, Antonova T, Yanova N, CHERNOS V . Antigenic properties of vaccinia virus and of the virus recombinant strains expressing heterologous genes. Acta Virol. 1988; 32(5):409-16. View

3.
Mackett M, Smith G, Moss B . Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci U S A. 1982; 79(23):7415-9. PMC: 347350. DOI: 10.1073/pnas.79.23.7415. View

4.
Mackett M, Smith G, Moss B . General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes. J Virol. 1984; 49(3):857-64. PMC: 255547. DOI: 10.1128/JVI.49.3.857-864.1984. View

5.
Chakrabarti S, Robert-Guroff M, Wong-Staal F, Gallo R, Moss B . Expression of the HTLV-III envelope gene by a recombinant vaccinia virus. Nature. 1986; 320(6062):535-7. DOI: 10.1038/320535a0. View